KR20120047262A - (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법 - Google Patents

(ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법 Download PDF

Info

Publication number
KR20120047262A
KR20120047262A KR1020127004225A KR20127004225A KR20120047262A KR 20120047262 A KR20120047262 A KR 20120047262A KR 1020127004225 A KR1020127004225 A KR 1020127004225A KR 20127004225 A KR20127004225 A KR 20127004225A KR 20120047262 A KR20120047262 A KR 20120047262A
Authority
KR
South Korea
Prior art keywords
duloxetine
crystalline
crystalline duloxetine
solvent
crystallization
Prior art date
Application number
KR1020127004225A
Other languages
English (en)
Korean (ko)
Inventor
루덱 리드반
조세프 시니불크
베로니카 그룬발도바
한나 브루소바
Original Assignee
젠티바, 케이.에스.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠티바, 케이.에스. filed Critical 젠티바, 케이.에스.
Publication of KR20120047262A publication Critical patent/KR20120047262A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
KR1020127004225A 2009-09-02 2010-09-02 (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법 KR20120047262A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
CZPV-2009-584 2009-09-02

Publications (1)

Publication Number Publication Date
KR20120047262A true KR20120047262A (ko) 2012-05-11

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004225A KR20120047262A (ko) 2009-09-02 2010-09-02 (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법

Country Status (11)

Country Link
EP (1) EP2473497A1 (zh)
JP (1) JP2013503823A (zh)
KR (1) KR20120047262A (zh)
CN (1) CN102482254A (zh)
BR (1) BR112012004862A2 (zh)
CZ (1) CZ304602B6 (zh)
EA (1) EA021528B1 (zh)
IL (1) IL218329A0 (zh)
MX (1) MX2012002621A (zh)
WO (1) WO2011026449A1 (zh)
ZA (1) ZA201201570B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
WO2004005239A1 (en) 2002-07-09 2004-01-15 Lonza Ag PROCESS FOR THE PREPARATION OF N-MONOSUBSTITUTED β-AMINO ALCOHOLS
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
EP1874754A1 (en) * 2005-03-14 2008-01-09 Teva Pharmaceutical Industries Ltd Pure duloxetine hydrochloride
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP2132192B1 (en) * 2007-03-05 2013-04-24 Lupin Limited Novel process for preparation of duloxetine hydrochloride

Also Published As

Publication number Publication date
EA201290127A1 (ru) 2013-02-28
CN102482254A (zh) 2012-05-30
CZ304602B6 (cs) 2014-07-30
ZA201201570B (en) 2013-08-28
IL218329A0 (en) 2012-04-30
EA021528B1 (ru) 2015-07-30
EP2473497A1 (en) 2012-07-11
WO2011026449A1 (en) 2011-03-10
MX2012002621A (es) 2012-07-03
CZ2009584A3 (cs) 2011-03-09
JP2013503823A (ja) 2013-02-04
BR112012004862A2 (pt) 2015-09-08

Similar Documents

Publication Publication Date Title
CA2114678C (en) Crystals of n-(trans-4-isopropylcyclohexylcarbonyl)- d-phenylalanine and methods for preparing them
BRPI0617477A2 (pt) mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CA2988393C (en) Solid state forms of sofosbuvir
KR20120047262A (ko) (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법
PT1020464E (pt) Metanossulfonato de paroxetina
WO2008146284A2 (en) Crystalline rotigotine base and preparation process therefor
CN102282125A (zh) 新方法和纯的多晶型物
JP2013503823A5 (zh)
JP4216072B2 (ja) ドーパミンｄ２受容体及びセロトニン再取り込み部位に対する高い親和性を有する８−｛４−［３−（５−フルオロー１ｈ−インドール−３−イル）−プロピル］−ピペラジン−１−イル｝−２−メチル−４ｈ−ベンゾ［１，４］オキサジン−３−オンメシラート
US8785435B2 (en) Solid forms
JPWO2005103017A1 (ja) 難溶性薬物の比表面積増大方法
EA017483B1 (ru) Стабильная кристаллическая соль 1-азабицикло[2.2.2]окт-3-илового сложного эфира (r)-3-фторфенил-3,4,5-трифторбензилкарбаминовой кислоты
EP1646607B1 (en) A method for the preparation of crystalline dexloxiglumide
AU2007274477B2 (en) Novel crystal of substituted phenylalkanoic acid and production process
Veverka et al. Crystal habit modifications of imatinib mesylate under various precipitation conditions
JP7326295B2 (ja) オキサゾール化合物結晶
CN112707829B (zh) 一种妥洛特罗晶型及制备方法
WO2024067542A1 (zh) 一种含螺环类衍生物的盐、晶型及其制备方法和应用
CA2642687A1 (en) Crystal form of besipirdine chlorhydrate, process preparation and use thereof
JPH11513394A (ja) 二置換ピペリジン誘導体
CN112079794A (zh) 含硒化合物及其治疗神经退行性疾病的用途
WO2011033470A1 (en) Crystalline form of montelukast sodium
CN101479248A (zh) 用作5-ht2a血清素受体调节剂的苯基-吡唑的晶型和其制备方法
JPS5931740A (ja) 二級アミン、その製法及びそれらを含む医薬組成物
JP2003206229A (ja) ファモチジン多形体ａとｂとの混合物の製造方法

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid